Lyell cautioned that the study was designed to detect a 50 percent improvement in delayed deliveries, and that any smaller advantages of nifedipine use would not have been spotted.
She thinks a larger study of nifedipine is warranted.
A small benefit would be especially significant at early gestational ages, and less so later on. But overall, there's no benefit to pre-maturity, she said.
Since there is a lack of data to support nifedipine use, Lyell believes obstetricians should proceed with caution.
All medications have side effects, she said.
The drug might be having a fairly good safety record, but some case reports link it to dangerously low blood pressure in pregnant women.
If something has not been shown to be of benefit, it shouldn't be used. Every now and then, there will be a patient who has an unusual side effect,Lyell said.
It's important to distinguish between acute treatment, which is given to a woman in pre-term labour, and maintenance treatment, which is given to a woman following an episode of pre-term labour that has ended. This study addresses maintenance treatment. We still use nifedipine for acute treatment of pre-term labour, she added.
The findings of the study will appear in the December issue of the journal Obstetrics and Gynecology.
Source-ANI
SPH